Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year. "We are currently in late-stage optimisation, and plan to have a clinical candidate by the end of the year," Addex's CEO Dr ...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
Somaxon's share price rose by 29% on the news, closing at $4.34 on Nasdaq on 25 August.
Somaxon said it was ...
Many pharmaceutical firms are expected to make objections to some of the new drug prices that were announced by the Greek government's pricing committee last week. Novartis and GlaxoSmithKline, two of the top five players in country in sales terms, ...
Eisai has reported positive results from the first Phase III clinical study with its non-competitive AMPA glutamate antagonist perampanel (E2007) as an adjunctive therapy in epilepsy patients with refractory partial seizures.
The 25-country study ...
A joint meeting on 20 August of two US FDA advisory committees put major roadblocks in the way of Jazz Pharmaceuticals' new drug application (NDA) to sell sodium oxybate as a treatment for fibromyalgia. The panel of outside experts on arthritis ...
